A retrospective study assessing the patterns of resistance potentially compared between patients developed resistance immediately or after an initial clinical benefit treated with Immune Checkpoint Inhibitors for metastatic Renal Cell Carcinoma
Latest Information Update: 15 Oct 2020
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress